PARP Inhibitors - Pipeline Insight, 2020

Publisher Name :
Date: 24-Nov-2020
No. of pages: 80
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "PARP Inhibitors- Pipeline Insight, 2020," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in PARP Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

PARP Inhibitors Understanding

PARP Inhibitors: Overview

PARP is a family of proteins loosely based on structural similarity and function. PARP proteins are composed of two ribose moieties and two phosphates per unit polymer. PARP1 and PARP2 are enzymes involved in a DNA repair pathway for SSBs called BER. The best-known PARP is PARP1. This enzyme was first reported in 1963. In 1980 Durkacz et al. proposed that modulating PARP1 might augment the effect of alkylator chemotherapy. PARP1 detects and binds to sites of single strand DNA damage via the DNA-binding domain. It then synthesizes poly (ADP) ribose (PAR) and transfers it to acceptor proteins. PAR recruits other repair proteins to the damaged DNA site. In the case of extreme DNA damage, as with ischemia, PARP1 hyperactivation induces depletion of NAD+ and ATP, resulting in cell death by necrosis or apoptosis. PAR is involved in double strand breaks (DSBs) repair as well. PAR recruits ATM, MRE11, and topoisomerase 1, which are involved in DSBs repair.

- All current PARP inhibitors in development are thought to inhibit both PARP1 and PARP2. Though nicotinamide's activity in inhibiting PARP was first noted in 1971, the exploration of this class of agent has recently become extensive. The first generation of inhibitors included nicotinamide analogues.

- In multiple PARPi-involved combination strategies, PARPi acts as sensitizers for chemotherapies, immunotherapies, and targeted therapies by limiting DNA damage repair. In addition, some targeted treatments such as MEK inhibitors could enhance the sensitivity of tumor cells and relieve the resistance to PARPi

PARP Inhibitors Emerging Drugs Chapters

This segment of the PARP Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

PARP Inhibitors Emerging Drugs

- Pamiparib: BeiGene

Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene's investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies

Further product details are provided in the report……..

PARP Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different PARP Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players working on PARP Inhibitors

There are approx. 30+ key companies which are developing the PARP Inhibitors. The companies which have their PARP Inhibitors drug candidates in the most advanced stage, i.e. phase III include, BeiGene.

- Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

- Late-stage products (Phase III and

- Mid-stage products (Phase II and

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

PARP Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Infusion

- Intradermal

- Intramuscular

- Intranasal

- Intravaginal

- Oral

- Parenteral

- Subcutaneous

- Topical.

- Molecule Type

Products have been categorized under various Molecule types such as

- Vaccines

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

PARP Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses PARP Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PARP Inhibitors drugs.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence PARP Inhibitors R&D. The therapies under development are focused on novel approaches for PARP Inhibitors.

- July 2020: Oncology Venture announced that it has secured the remaining ownership in its priority PARP inhibitor (2X-121) program along with its 2X-111 program, by acquiring all outstanding shares in Oncology Venture US Inc. (formerly 2X Oncology, Inc.) from its external shareholders and warrantholders. As a result of the transaction, the Company now has 100 % ownership of 2X-121, which is being clinically developed as an anti-cancer therapeutic, as well as being tested as an anti-viral agent against COVID-19. Similarly, the Company now has 100% ownership of 2X-111, which is being clinically developed as an anti-cancer therapeutic via a recently announced license agreement with Smerud Medical Research International.

PARP Inhibitors Report Insights

- PARP Inhibitors Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

PARP Inhibitors Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

- How many companies are developing PARP Inhibitors drugs?

- How many PARP Inhibitors drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for PARP Inhibitors?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the PARP Inhibitors therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for PARP Inhibitors and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- TESARO

- AstraZeneca

- Sun BioPharma

- Eisai Co

- BeiGene

- IMPACT Therapeutics

- Ribon Therapeutics

Key Products

- Niraparib

- Olaparib

- SBP 101

- 2X 121

PARP Inhibitors - Pipeline Insight, 2020

Table of Contents

Introduction
Executive Summary
PARP Inhibitors: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
PARP Inhibitors - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• PARP Inhibitors companies' collaborations, Licensing, Acquisition -Deal Value Trends
PARP Inhibitors Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Pamiparib: BeiGene
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
PARP Inhibitors Key Companies
PARP Inhibitors Key Products
PARP Inhibitors- Unmet Needs
PARP Inhibitors- Market Drivers and Barriers
PARP Inhibitors- Future Perspectives and Conclusion
PARP Inhibitors Analyst Views
PARP Inhibitors Key Companies
Appendix


List of Tables

Table 1 Total Products for PARP Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products


List of Figures

Figure 1 Total Products for PARP Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Recombinant Human Erythropoietin (rhEPO) Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 99
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - ESRD - Cancer - HIV - Wounds and Neural Disease Segment by Application - Hospi......
  • Global rhEPO Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 97
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - ESRD - Cancer - HIV - Wounds and neural disease Segment by Application - Hospi......
  • Global Rhematoid Arthritis Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 94
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Pharmaceuticals - Biopharmaceuticals Segment by Application - Prescription - OTC......
  • Global Chronic Obstructive Pulmonary Disease Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 118
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Inhalers - Nebulizers Segment by Application - Emphysema - Chronic Bronchitis ......
  • Global Chronic Lymphocytic Leukemia Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 121
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Acutemyeloid (ormyelogenous)leukemia (AML) - Chronicmyeloid (ormyelogenous)leukemia (CML) - Acutelymphocyti......
  • Global Chemotherapy-induced Nausea and Vomiting Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 93
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - 5-HT3 Inhibitors - NK1 Inhibitors - Other Segment by Application - Highly Emetogenic ......
  • Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 120
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Aloxi (Palonosetron) - Kytril Generic (Granisetron) - Emend (Aprepitant) - Akynzeo (Netupitant-Palon......
  • Global ß-blockers Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 122
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Nonselective Agents - Selective Agents Segment by Application - Abnormal Heart Rhythms......
  • Global a-adrenoreceptor Antagonists Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 116
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Non-selective Antagonists - Selective Antagonists Segment by Application - Hypertension......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs